Alivus Life Sciences Q2FY27 Revenue up 16% YoY to ₹682 Crore, EBITDA Margins at 41.8%
Alivus Life Sciences reported Q2FY27 revenue growth of 16.0% YoY to ₹682 crore. EBITDA margins reached a record high of 41.8%, up 880 bps YoY. PAT grew 51.3% YoY to ₹196.8 crore. The company generated ₹270 crore free cash flow in H1FY27, with cash reserves of ₹1,011.6 crore.
The results show significant improvement in key financial metrics and operational efficiency, indicating strong business performance and positive future outlook, which is material for investors.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with record-high EBITDA margins and robust free cash flow generation. Management commentary is optimistic about future growth.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced its financial results for the second quarter and half-year ended September 30, 2026. Revenue from operations for Q2FY27 grew by 16.0% year-on-year to ₹6,820 million (₹682 crore), primarily driven by a 20.8% YoY growth in the non-GPL business.
For the half-year ended H1FY27, revenue from operations stood at ₹13,224 million (₹1,322.4 crore), an increase of 11.1% YoY. EBITDA for Q2FY27 surged by 47.0% YoY to ₹2,851 million (₹285.1 crore), with margins reaching a record high of 41.8%, up 520 basis points quarter-on-quarter and 880 basis points year-on-year. This improvement was attributed to a favorable product mix, new launches, and operating leverage.
EBITDA for H1FY27 was ₹5,192 million (₹519.2 crore), a 38.4% YoY growth with margins at 39.3%. Profit After Tax (PAT) for Q2FY27 increased by 51.3% YoY to ₹1,968 million (₹196.8 crore), with PAT margins at 28.9%. For H1FY27, PAT was ₹3,569 million (₹356.9 crore), a 41.9% YoY growth with margins at 27.0%.
The company generated a strong free cash flow of ₹2,702 million (₹270.2 crore) in H1FY27, leading to cash and cash equivalents of ₹10,116 million (₹1,011.6 crore) as of September 30, 2026. The company maintains a healthy, debt-free balance sheet.
Dr. Yasir Rawjee, MD & CEO, highlighted the strong revenue growth and contributions from recent launches, noting a pick-up in the CDMO business. He expressed confidence in sustaining momentum and delivering consistent growth, supported by ongoing capacity expansion and a healthy development pipeline.
Tushar Mistry, CFO, emphasized the strong financial performance, improved profitability, and robust cash generation. He stated the company's focus on sustaining profitable growth, maintaining financial discipline, and creating long-term value, supported by ample financial flexibility for growth initiatives.
Additional highlights include 630 cumulative DMF/CEP filings by September 30, 2026. The company filed 10 patents and was granted 3 in H1FY27, bringing cumulative patent grants to 88. The HP API portfolio has 30 APIs in the active grid.
Capex updates include the ongoing construction for Phase 1 (Intermediate block) and Phase 2 (API/Pharma block) at Solapur, expected to be completed in Q3 FY27 and Q4 FY27, respectively. Construction of the new R&D facility in Taloja is also progressing steadily.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.